French Insurer CNP Assurances' Proposed Subordinated Notes Rated 'A'

  • ID: 1753688
  • March 2011
  • Region: France
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

France-based CNP Assurances plans to issue fixed-to-floating-rate unsecured subordinated callable notes due in September 2041. We are assigning an 'A' issue rating to the proposed notes. We expect to classify the notes as having "intermediate equity content" according to our hybrid capital criteria. PARIS (Standard & Poor's) March 31, 2011--Standard & Poor's Ratings Services said today that it has assigned its 'A' long-term issue rating to the proposed unsecured subordinated callable notes due in September 2041 to be issued by French insurer CNP Assurances (AA-/Stable/--). The rating on the notes is subject to confirmation, following our receipt and review of the final terms and conditions. The rating is two notches below our counterparty credit rating on CNP, reflecting our standard...

Companies mentioned in this report are: CNP Assurances
Action: New Rating

Note: Product cover images may vary from those shown
2 of 3

CNP Assurances

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.